HER2 testing represents a cornerstone of the treatment algorithm in advanced gastric and gastroesophageal junction adenocarcinoma (GC), yet its evaluation remains complex due to tumor heterogeneity and methodological variability. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.